About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 417 record(s)
Req # A-2023-000427
Every final Harassment and Violence investigation report completed during the months of April and May, 2023. These reports are prepared in accordance with the Work Place Harassment and Violence Prevention Regulations.Organization: Health Canada
June 2023
Req # A-2019-002036
Adverse Drug Reactions (ADRs). Report numbers: E2B_02791907, E2B_02791921, E2B_02791925, E2B_02791973, E2B_02406472, E2B_02880510, E2B_02828479.Organization: Health Canada
June 2023
Req # A-2020-000348
Adverse Drug Reactions (ADRs) for HYOSCINE BUTYLBROMIDE. Report numbers: 730245, E2B_02772414.Organization: Health Canada
June 2023
Req # A-2020-000976
Adverse Drug Reactions (ADRs). Report numbers: E2B_01802327, E2B_02907791, E2B_03034122, E2B_02733252, E2B_02853060, E2B_03195983, 000912972, 000913059, E2B_02017137, E2B_02794019, E2B_03115387, E2B_02749590, E2B_02972720, E2B_02974863, 000912918, E2B_02800383, E2B_02885467, E2B_03068603, 000910227.Organization: Health Canada
June 2023
Req # A-2020-001527
Adverse Drug Reactions (ADRs). Report numbers: E2B_03051594, E2B_03051611, E2B_03052004, E2B_03052412, E2B_03052529, E2B_03052678, E2B_03052735, E2B_03053646, E2B_03053857, E2B_03055141, E2B_03055340, E2B_03055614, E2B_03056320, E2B_03056588, E2B_03056590, E2B_03056592, E2B_03057449, E2B_03057608, E2B_03059155, E2B_03059495.Organization: Health Canada
June 2023
Req # A-2021-000300
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-107275-641.Organization: Health Canada
June 2023
Req # A-2022-000679
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-107513-489.Organization: Health Canada
June 2023
Req # A-2022-000967
Adverse Drug Reactions (ADRs). Report numbers: E2B_05557663, E2B_05529145, E2B_05548027, E2B_05586452, E2B_05564919, E2B_05564937, E2B_05564942, E2B_05565776, E2B_05565040, E2B_05580369.Organization: Health Canada
June 2023
Req # A-2022-001016
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-109293-438.Organization: Health Canada
June 2023
Req # A-2022-001149
Adverse Drug Reactions (ADRs). Report numbers: E2B_05390581, E2B_05387196, E2B_05404106, E2B_04238483, E2B_05414596, E2B_05374871, 000994163, E2B_05395217, E2B_05250178, E2B_05387214.Organization: Health Canada
June 2023